** Shares of Telix Pharmaceuticals TLX.AX rise 2.9% to A$25.52, on track for best day since June 4
** TLX among top gainers on the benchmark index .AXJO
** The biopharma co announced on Friday after market hours that its prostate cancer imaging agent Illuccix was granted marketing authorization by the National Organization for Medicines $(EOF.AU)$ of Greece
** Stock up 3.6% YTD, including moves in current session
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.